Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone + polymyxin b sulfate + bacitracin zinc + neomycin is a marketed fixed-dose ophthalmic anti-infective and corticosteroid combination, historically sold under the brand name Cortisporin. It combines **hydrocortisone**, a glucocorticoid receptor agonist that suppresses ocular inflammation, with **neomycin**, **polymyxin B**, and **bacitracin**, antibacterial agents that broaden topical coverage against susceptible bacterial eye pathogens by inhibiting ribosomal protein synthesis, disrupting the bacterial outer membrane, and inhibiting bacterial cell wall synthesis, respectively. The ointment has been used for steroid-responsive inflammatory ocular conditions where bacterial infection is present or there is risk of infection, including inflammatory conditions of the conjunctiva, cornea, and anterior segment of the globe, chronic anterior uveitis, and corneal injury from chemical, radiation, or thermal burns or foreign body penetration. The ophthalmic ointment formulation described in labeling contains hydrocortisone 1% with neomycin sulfate, polymyxin B sulfate, and bacitracin zinc in a petrolatum and mineral oil base.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone + polymyxin b sulfate + bacitracin zinc + neomycin.